Gene therapy for epilepsy

Abstract

Focal epilepsies present an attractive target for viral vector gene therapy especially in those cases approved for surgical resection. A number of basic studies have identifi ed potential therapeutic approaches ranging from neuroactive peptides and potassium channels to DREADD receptors. Although each approach exhibits clear therapeutic strengths, a number of concerns remain. Immune responses, variable cellular tropisms, off-target liabilities, and surgical infusion parameters must be considered in order to move these therapies to the clinic.